These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 36510618)

  • 1. How Efficient are Alendronate-Nano/Biomaterial Combinations for Anti-Osteoporosis Therapy? An Evidence-Based Review of the Literature.
    Klara J; Lewandowska-Łańcucka J
    Int J Nanomedicine; 2022; 17():6065-6094. PubMed ID: 36510618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment for osteoporosis in people with ß-thalassaemia.
    Bhardwaj A; Swe KM; Sinha NK; Osunkwo I
    Cochrane Database Syst Rev; 2016 Mar; 3():CD010429. PubMed ID: 26964506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term delivery of alendronate through an injectable tetra-PEG hydrogel to promote osteoporosis therapy.
    Li D; Zhou J; Zhang M; Ma Y; Yang Y; Han X; Wang X
    Biomater Sci; 2020 Jun; 8(11):3138-3146. PubMed ID: 32352105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
    Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
    Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards Controlling the Local Bone Tissue Remodeling-Multifunctional Injectable Composites for Osteoporosis Treatment.
    Klara J; Onak S; Kowalczyk A; Horak W; Wójcik K; Lewandowska-Łańcucka J
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term use of bisphosphonates in osteoporosis.
    Watts NB; Diab DL
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of bone loss and improvement of pain-related behavior in hind limb-unloaded mice by administration of teriparatide and bisphosphonate.
    Miyamura G; Wakabayashi H; Nagao N; Kato S; Nakagawa T; Naito Y; Sudo A
    Mod Rheumatol; 2021 May; 31(3):733-742. PubMed ID: 32646253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.
    Fleurence RL; Iglesias CP; Johnson JM
    Pharmacoeconomics; 2007; 25(11):913-33. PubMed ID: 17960951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
    J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time trends in oral bisphosphonate initiation in Ontario, Canada over 20 years reflect drug policy and healthcare delivery changes.
    Hayes KN; Ban JK; Athanasiadis G; Burden AM; Cadarette SM
    Osteoporos Int; 2019 Nov; 30(11):2311-2319. PubMed ID: 31317249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
    Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
    Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
    Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
    Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alendronate-loaded, biodegradable smart hydrogel: a promising injectable depot formulation for osteoporosis.
    Nafee N; Zewail M; Boraie N
    J Drug Target; 2018 Aug; 26(7):563-575. PubMed ID: 29073792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained delivery of alendronate by engineered collagen scaffold for the repair of osteoporotic bone defects and resistance to bone loss.
    Zeng Y; Zhou M; Mou S; Yang J; Yuan Q; Guo L; Zhong A; Wang J; Sun J; Wang Z
    J Biomed Mater Res A; 2020 Dec; 108(12):2460-2472. PubMed ID: 32419333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
    Eisman JA; Cortet B; Boolell M; Ionescu-Ittu R; Vekeman F; Heroux J; Thomasius F
    Osteoporos Int; 2023 May; 34(5):977-991. PubMed ID: 36872338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic.
    Craig SJ; Youssef PP; Vaile JH; Sullivan L; Bleasel JF
    Intern Med J; 2011 Feb; 41(2):186-90. PubMed ID: 20214696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can the alendronate dosage be altered when combined with high-frequency loading in osteoporosis treatment?
    Correa CB; Camargos GV; Chatterjee M; Mesquita MF; Del Bel Cury AA; Naert I; Duyck J; Vandamme K
    Osteoporos Int; 2017 Apr; 28(4):1287-1293. PubMed ID: 27921147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A risk-benefit assessment of alendronate in the treatment of involutional osteoporosis.
    Devogelaer JP
    Drug Saf; 1998 Aug; 19(2):141-54. PubMed ID: 9704250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study.
    Bliuc D; Tran T; van Geel T; Adachi JD; Berger C; van den Bergh J; Eisman JA; Geusens P; Goltzman D; Hanley DA; Josse RG; Kaiser S; Kovacs CS; Langsetmo L; Prior JC; Nguyen TV; Center JR;
    Osteoporos Int; 2019 Apr; 30(4):817-828. PubMed ID: 30607457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.